How We Chose
We tracked healthcare funding rounds announced between September 22 and October 27, 2026 and kept partners at venture or growth firms credited with leading the round, quoted in the announcement, or joining the board. We favored rounds in companies under $500 million in revenue. Entries are in alphabetical order by last name.
Hottest Healthcare Industry Investors (November 2026)
| # | Name | Firm | Why now |
|---|
| 1 | Vineeta Agarwala | Andreessen Horowitz | Led General Medicine's $120M Series B |
| 2 | Vig Chandramouli | Oak HC/FT | Vitalize's $31M Series A, Oct 6 |
| 3 | Mike Dixon | Transformation Capital | Abby Care's $82M Series C |
| 4 | Aman Mahajan | Healthier Capital | Suki's $90M Series E, Oct 13 |
| 5 | Nikhil Marathe | F-Prime | AblePay's $20M Series A, Oct 7 |
| 6 | Emily Melton | Threshold Ventures | Vera Health's $28.5M Series A, Oct 27 |
| 7 | Heidi Patel | Rethink Impact | Allswell's $7M seed, Oct 14 |
| 8 | Blake Wu | NEA | Basalt's $20M Series A, Sep 24 |
$120MLed General Medicine's Series B
1. Vineeta Agarwala
General Partner, Andreessen Horowitz
- Notable bet
- General Medicine
- Why now
- Led General Medicine's $120 million Series B, announced October 6, 2026.
Agarwala is a general partner at Andreessen Horowitz, where she invests across biotech, life sciences software, and digital health. She is a physician who still sees patients at Stanford, and she earlier built oncology data products at Flatiron Health.
Why now
In a16z’s post on the deal, Agarwala and three colleagues wrote that they were "thrilled that the PillPack team is back together." The bet is on a store model for care whose revenue is not public yet.
Vineeta Agarwala profileGeneral Medicine review
$31MOak HC/FT led Vitalize's Series A
2. Vig Chandramouli
Partner, Oak HC/FT
- Notable bet
- Vitalize
- Why now
- Oak HC/FT led Vitalize's $31 million Series A, announced October 6, 2026.
Chandramouli has invested in health care at Oak HC/FT since 2014. He grew up in a small town in South India, where his grandfather, a doctor, saw 40 to 50 patients a day.
Why now
"Labor is a nearly trillion-dollar line item for U.S. health systems," he said in the announcement. Vitalize's results so far come from customers it cites.
Vig Chandramouli profileVitalize review
$82MTransformation Capital led Abby Care's Series C
3. Mike Dixon
Managing Partner, Transformation Capital
- Notable bet
- Abby Care
- Why now
- Transformation Capital led Abby Care's $82 million Series C in October 2026.
Dixon is a managing partner at Transformation Capital, a growth equity firm that invests only in digital health. He was earlier a general partner at Sequoia Capital, where he helped lead investments in Health Catalyst, Clover Health, and MedExpress.
Why now
"We believe Abby Care has the opportunity to build the infrastructure that makes family caregiving a standard option for at-home care across the country," Dixon said in the announcement. The bet rests on state Medicaid programs continuing to pay family caregivers.
Mike Dixon profileAbby Care review
$90MHealthier Capital led Suki's Series E
4. Aman Mahajan
Partner, Healthier Capital
- Notable bet
- Suki
- Why now
- Healthier Capital led Suki's $90 million Series E, announced October 13, 2026.
Mahajan is an anesthesiologist and physician-scientist who chaired anesthesiology departments at UCLA Health and the University of Pittsburgh Medical Center, then led health innovation and venture investing at UPMC before joining Healthier Capital.
Why now
He joined Suki's board with the round. "The real opportunity for AI in healthcare isn't to automate individual tasks," he said in the announcement. Suki is a later-stage bet in a crowded ambient AI market.
Aman Mahajan profileSuki review
$20MF-Prime led AblePay Health's Series A
5. Nikhil Marathe
Principal, F-Prime
- Notable bet
- AblePay Health
- Why now
- F-Prime led AblePay Health's $20 million Series A, announced October 7, 2026.
Marathe works on venture growth investments in health care software and services at F-Prime. He spent 13 years at Silversmith Capital Partners and TA Associates before joining.
Why now
"AblePay has built a differentiated model that addresses a significant market pain point for both healthcare providers and patients," he said in the announcement. AblePay does not publish volume figures, so the size of that opportunity is hard to check.
Nikhil Marathe profileAblePay Health review
$28.5MThreshold led Vera Health's Series A
6. Emily Melton
Co-founder and Managing Partner, Threshold Ventures
- Notable bet
- Vera Health
- Why now
- Threshold led Vera Health's $28.5 million Series A, announced October 27, 2026.
Melton co-founded Threshold Ventures and has backed health companies including Livongo, Brightline, Elation Health, Transcarent, and Viz. She chaired the National Venture Capital Association for the 2022-23 term.
Why now
"By bringing that evidence to the point of care, Vera becomes a trusted clinical intelligence layer, not just another AI tool," she said in the announcement. Vera is free for clinicians, so the return depends on partnerships it has not yet detailed.
Emily Melton profileVera Health review
$7MRethink Impact led Allswell's seed round
7. Heidi Patel
Managing Partner, Rethink Impact
- Notable bet
- Allswell
- Why now
- Rethink Impact led Allswell's $7 million seed round, announced October 14, 2026.
Patel is a managing partner at Rethink Impact, which invests in female-led technology companies, and was an early investor in Spring Health. She co-created and teaches a course on impact investing at Stanford's Graduate School of Business.
Why now
"Only 5% of Gen X identifies as LGBTQ+, compared with 25% of Gen Z," she said in the announcement. Allswell is small, with an estimated $2 million or less in annual revenue.
Heidi Patel profileAllswell review
$20MNEA led Basalt Health's Series A
8. Blake Wu
Partner, NEA
- Notable bet
- Basalt Health
- Why now
- NEA led Basalt Health's $20 million Series A, announced September 24, 2026.
Wu has invested in digital health and biopharmaceutical companies at NEA since 2014. NEA backed Basalt in its seed round, and Wu sits on its board.
Why now
"The company's AI-powered platform is becoming essential infrastructure for care teams," Wu said in the announcement. The rollout across 111 Lifepoint and ScionHealth markets by year end will show whether that holds.
Blake Wu profileBasalt Health review
What to Watch Next Month
- Basalt's rollout. Blake Wu's bet faces its test as Basalt rolls out to 111 Lifepoint and ScionHealth markets by the end of 2026.
- State caregiver pay. State decisions on Medicaid pay for family caregivers will shape Abby Care, the company Transformation Capital backed in this window.
- Vera's partnerships. Vera Health plans partnerships with medical societies, publishers, and health systems, the first sign of how Threshold's free-tool bet earns money.
The Hottest Healthcare Industry Investors list is updated monthly. This is the first edition. Past editions will be linked here, and every HIR list and report is in our research library.
